For Sun Pharma, its investment in speciality business is paying off, as it is becoming a driver of growth for the company’s US business. Cipla’s ‘One India’ strategy, focusing on branded prescription, trade generics and consumer health brands, is leading to continued core portfolio momentum across businesses.
Valuations turn attractive as markets look beyond uncertainty: A Balasubramanian
Amidst geopolitical uncertainty, market expert A Balasubramanian suggests the worst may be nearing an end, with improving macro signals and reasonable valuations in Indian equities.